NCT03138421View on ClinicalTrials.gov

Central Pain Study for ABX-1431

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

July 23, 2018

Study Completion Date

July 24, 2018

Conditions
Neuromyelitis Optica Spectrum DisorderTransverse MyelitisMultiple SclerosisLongitudinally Extensive Transverse Myelitis
Interventions
DRUG

ABX-1431 HCl

ABX-1431 HCl, capsules, 20 mg

DRUG

Placebo

Matching placebo

Trial Locations (2)

L97LJ

The Walton Centre, Liverpool

OX3 9DU

Oxford University Hospitals NHS Foundation Trust, Oxford

Sponsors

Lead Sponsor

Abide Therapeutics
All Listed Sponsors
lead

Abide Therapeutics

INDUSTRY

NCT03138421 - Central Pain Study for ABX-1431 | Biotech Hunter | Biotech Hunter